• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Belite Bio, Inc - American Depositary Shares (NQ: BLTE )

    69.90 +3.29 (+4.94%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Belite Bio, Inc - American Depositary Shares

    < Previous 1 2 3 4 5 Next >
    Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting
    From Belite Bio, Inc
    Via GlobeNewswire
    Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit
    From Belite Bio, Inc
    Via GlobeNewswire
    Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease
    From Belite Bio, Inc
    Via GlobeNewswire
    Expert Ratings for Belite Bio
    Via Benzinga
    Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
    Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
    From Virtual Investor Conferences
    Via GlobeNewswire
    Belite Bio to Participate in Three Upcoming Investor Conferences
    From Belite Bio, Inc
    Via GlobeNewswire
    International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024
    From Virtual Investor Conferences
    Via GlobeNewswire
    Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer
    From Belite Bio, Inc
    Via GlobeNewswire
    BLTE Stock Earnings: Belite Bio Misses EPS for Q2 2024
    BLTE stock results show that Belite Bio missed analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
    From Belite Bio, Inc
    Via GlobeNewswire
    Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
    From Belite Bio, Inc
    Via GlobeNewswire
    Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results
    From Belite Bio, Inc
    Via GlobeNewswire
    Belite Bio to Present at the JonesHealthcare Seaside Summit
    From Belite Bio, Inc
    Via GlobeNewswire
    Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan
    From Belite Bio, Inc
    Via GlobeNewswire
    Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference
    From Belite Bio, Inc
    Via GlobeNewswire
    BLTE Stock Earnings: Belite Bio Misses EPS for Q1 2024
    BLTE stock results show that Belite Bio missed analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
    From Belite Bio, Inc
    Via GlobeNewswire
    Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
    From Belite Bio, Inc
    Via GlobeNewswire
    Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results
    From Belite Bio, Inc
    Via GlobeNewswire
    Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant
    From Belite Bio, Inc
    Via GlobeNewswire
    Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting
    From Belite Bio, Inc
    Via GlobeNewswire
    Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting
    From Belite Bio, Inc
    Via GlobeNewswire
    Belite Bio Announces $25 Million Registered Direct Offering
    From Belite Bio, Inc
    Via GlobeNewswire
    Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
    From Belite Bio, Inc
    Via GlobeNewswire
    Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
    From Belite Bio, Inc
    Via GlobeNewswire
    Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
    From Belite Bio, Inc
    Via GlobeNewswire
    Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results
    From Belite Bio, Inc
    Via GlobeNewswire
    Belite Bio to Participate in the Leerink Partners Global Biopharma Conference
    From Belite Bio, Inc
    Via GlobeNewswire
    Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
    From Belite Bio, Inc
    Via GlobeNewswire
    Belite Bio to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
    From Belite Bio, Inc
    Via GlobeNewswire
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.